There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atricure (ATRC – Research Report), Ascendis Pharma (ASND – Research Report) and G1 Therapeutics (GTHX – Research Report) with bullish sentiments.
Atricure (ATRC)
In a report released today, Daniel Stauder from JMP Securities reiterated a Buy rating on Atricure, with a price target of $60.00. The company’s shares closed last Monday at $34.15, close to its 52-week low of $32.17.
According to TipRanks.com, Stauder is ranked #5061 out of 8651 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atricure with a $54.86 average price target, implying a 53.3% upside from current levels. In a report issued on January 4, Needham also maintained a Buy rating on the stock with a $44.00 price target.
See today’s best-performing stocks on TipRanks >>
Ascendis Pharma (ASND)
In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Ascendis Pharma, with a price target of $207.00. The company’s shares closed last Monday at $128.93, close to its 52-week high of $130.47.
According to TipRanks.com, Argyrides is a 3-star analyst with an average return of
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $149.55, implying a 14.2% upside from current levels. In a report issued on January 5, J.P. Morgan also maintained a Buy rating on the stock with a $146.00 price target.
G1 Therapeutics (GTHX)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics, with a price target of $9.00. The company’s shares closed last Monday at $3.51.
According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for G1 Therapeutics with a $9.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATRC:
